Bioregenx (BRGX) Payables (2021 - 2026)

Bioregenx has reported Payables for 6 years, with the latest figure at $1.7 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 73.33% year-over-year to $1.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.7 million (up 73.33% YoY), and the FY2025 full-year result was $1.6 million, up 23.53% from the prior year.
• Payables for Q1 2026 stood at $1.7 million, up from $1.6 million in the prior quarter.
• The five-year high for Payables was $1.7 million in Q1 2026, with the low at $34923.0 in Q1 2023.
• Average Payables over 5 years is $945716.9, with a median of $1.3 million recorded in 2024.
• Year-over-year, Payables soared 3394.4% in 2024 and fell 21.92% in 2025.
• Tracing BRGX's Payables over 5 years: stood at $60691.0 in 2022, then jumped by 917.24% to $617376.0 in 2023, then jumped by 112.31% to $1.3 million in 2024, then grew by 23.53% to $1.6 million in 2025, then climbed by 2.0% to $1.7 million in 2026.
• The last three Payables figures came in at $1.7 million (Q1 2026), $1.6 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.

Peer Comparison